Twist Bioscience Corporation (NASDAQ:TWST) reported fiscal first-quarter 2026 revenue that came in ahead of market expectations on Monday, prompting a rally in the stock, even though earnings fell short of forecasts.
Shares of the biotech group were up about 5.16% in premarket trading following the announcement.
Twist posted quarterly revenue of $103.7 million for the period ended December 31, 2025, beating the analyst consensus of $100.72 million and marking a 17% increase from $88.7 million a year earlier. The company, however, reported a net loss of $0.50 per share, wider than analysts’ expectations for a loss of $0.43 per share.
Encouraged by the stronger-than-expected top-line performance, management raised its full-year fiscal 2026 revenue guidance to a range of $435 million to $440 million, up from the prior outlook of $425 million to $435 million. The company also reiterated its goal of reaching adjusted EBITDA breakeven by the fourth quarter.
“We’re continuing to build on the momentum we established in fiscal 2025, starting the new fiscal year with our twelfth consecutive quarter of growth,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Revenue of $103.7 million exceeded guidance and increased 17% compared to the first quarter of 2025.”
Profitability metrics also improved, with gross margin rising to 52.0% in the quarter, up roughly four percentage points from 48.3% in the same period last year. Twist shipped products to around 2,538 customers during the quarter, compared with 2,376 customers in the first quarter of fiscal 2025.
Looking ahead, the company expects second-quarter revenue of approximately $107 million to $108 million, implying about 16% year-on-year growth. Twist also said it anticipates gross margin will remain above 52% for the full 2026 fiscal year.
As of December 31, 2025, the company reported approximately $198 million in cash, cash equivalents and short-term investments.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.